Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
841-860 of 3,900 trials

Chronic Kidney Disease: Patiromer Study

We are testing whether patiromer helps patients with chronic kidney disease better manage their blood pressure and reduce protein in urine. This study aims to improve treatment options for those with advanced kidney disease.

Chronic Kidney Disease6-12 monthsMonitoring phase (IV)6-10 visitsInvestigational MedicinesCost ReimbursementCardiologyNephrology

Lupus Treatment: BIIB059 Study

We are testing a new medication, BIIB059, for people with active subacute or chronic cutaneous lupus who haven't responded to standard treatments. The study aims to see if it can reduce skin disease activity and improve overall safety.

Skin Lupus1-2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyRheumatology

Atypical Hemolytic Uremic Syndrome: Crovalimab for Kids

We are studying the safety and effectiveness of crovalimab in children with atypical hemolytic uremic syndrome. This trial includes both new patients and those switching from other treatments.

Atypical Hemolytic Uremic Syndrome6-12 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyNephrology

Metastatic Neuroendocrine Prostate Cancer: Targeted Radioligand Therapy

We are exploring a new targeted treatment for patients with metastatic neuroendocrine prostate cancer. This study aims to assess its safety and effectiveness compared to existing therapies.

Metastatic Neuroendocrine Prostate Cancer>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Cholangiocarcinoma: Tinengotinib Study

We are studying the safety and effectiveness of a new oral medication, tinengotinib, for patients with FGFR-altered cholangiocarcinoma that hasn't responded to other treatments. This trial compares tinengotinib to the physician's choice of treatment.

Cholangiocarcinoma6-12 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteOncology

Non-Small-Cell Lung Cancer: Amivantamab Treatment Study

We are studying the effects of a new antibody treatment, amivantamab, alone and with chemotherapy for patients with early-stage lung cancer. This research aims to see if it helps before surgery and how it affects tumor characteristics.

Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutation>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Epithelial Ovarian Cancer: Sentinel Node Detection Study

We are testing two tracers to see if they improve the detection of sentinel lymph nodes in patients with early-stage epithelial ovarian cancer. This may help in better understanding the cancer's spread and improving surgical outcomes.

Ovarian Epithelial Cancer>2 yearsEfficacy phase (II)Standard MedicinesGynecology and ObstetricsOncology

Hypophosphatasia: ALXN1850 Treatment Study

We are studying a new treatment called ALXN1850 for adolescents and adults with hypophosphatasia who haven't been treated before. The goal is to see if it improves their daily functioning and quality of life compared to a placebo.

Hypophosphatasia>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteEndocrinologyHematology

Hypophosphatasia in Children: ALXN1850 Study

We are studying a new treatment, ALXN1850, for children with hypophosphatasia who haven't been treated before. The goal is to see if it improves bone health and quality of life compared to a placebo.

Hypophosphatasia3-6 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteOrthopedics and TraumatologyPediatrics

Ulcerative Colitis: Lutikizumab Treatment Study

We are assessing the safety and effectiveness of lutikizumab in adults with active ulcerative colitis. This study compares it to an existing treatment to see if it offers better results.

Ulcerative Colitis1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Postoperative Pain Relief: Ibuprofen and Tramadol Combination

We are studying a new combination treatment for patients with severe pain after surgery to see if it provides better pain relief than tramadol alone and a placebo. This trial aims to assess both effectiveness and safety.

Acute Pain6-12 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesInternal MedicineOrthopedics and TraumatologyOtolaryngology

Axial Spondyloarthritis: Imaging with Technetium-labeled Certolizumab Pegol

We are studying whether a new imaging method can improve treatment decisions for people with axial spondyloarthritis. This may help doctors better assess disease activity and predict treatment responses.

Axial Spondyloarthritis>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesInternal MedicineRheumatology

Advanced Non-Small Cell Lung Cancer: OSIBOOST 2 Study

We are testing a modified dosing strategy of osimertinib, with or without a booster drug, for patients with advanced EGFR mutated NSCLC. This study aims to improve treatment cost-effectiveness and reduce side effects while maintaining effectiveness.

Non-Small Cell Lung Cancer with an EGFR Mutation≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementOncologyPulmonology

Fosigotifator for Vanishing White Matter Disease

We are exploring the safety and tolerability of Fosigotifator in adults and children with Vanishing White Matter Disease. This study aims to understand how the body handles this new treatment.

Vanishing White Matter Disease>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurology

Prostate Cancer: Abiraterone and Oxycodone Study

We are investigating how abiraterone affects the metabolism of oxycodone in men with prostate cancer. This may help improve pain management for patients using these medications.

Prostate Cancer≤3 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesInternal MedicineOncologyUrology

HER2-Positive Biliary Tract Cancer: GemCis with Trastuzumab and Pembrolizumab

We are studying a combination of treatments for people with HER2-positive biliary tract cancer to see if it improves response rates and overall survival. This trial aims to assess both the effectiveness and safety of the treatment.

Cholangiocarcinoma and Gallbladder Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Head Trauma: Safety of Inhaled Isoflurane

We are evaluating the safety of using inhaled Isoflurane for sedation in patients with head trauma. This study aims to ensure that this method is safe for these patients.

Head Trauma>2 yearsEfficacy phase (II)Internal MedicineNeurologyOtolaryngology

End-Stage Renal Disease: Rivaroxaban Dosing Study

We are studying different doses of rivaroxaban to find the safest option for patients on chronic hemodialysis. The trial will also look at the risk of bleeding with each dose.

Chronic Hemodialysis≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineNephrology

Graft-versus-Host Disease: MC0518 Treatment Study

We are testing a new treatment, MC0518, for adults and adolescents with steroid-refractory acute graft-versus-host disease after stem cell transplantation. The study aims to see if it works better than the best available therapy and how it affects patients' quality of life.

Steroid Refractory Acute Graft Versus Host DiseaseConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Lung Cancer Treatment: Telisotuzumab Vedotin vs. Docetaxel

We are studying a new intravenous treatment for adults with previously treated non-squamous non-small cell lung cancer. The trial aims to see if it improves survival and quality of life compared to standard therapy.

Non-Squamous Non-Small Cell Lung CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology